FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213213079> ?p ?o ?g. }

• W4213213079 endingPage "256" @default.
• W4213213079 startingPage "256" @default.
• W4213213079 abstract "256 Background: Patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) are primarily older, have comorbidities, and take concomitant medications. Darolutamide (DARO), a structurally distinct and highly potent androgen receptor inhibitor, significantly reduced the risk of metastasis by ̃2 years and the risk of death by 31% versus placebo (PBO) and demonstrated favorable safety and tolerability in the phase 3 ARAMIS trial. DARO also has low potential for drug−drug interactions. This post hoc analysis of ARAMIS evaluated overall survival (OS) and safety in pts with ongoing comorbidities and concomitant medications. Methods: Pts with nmCRPC were randomized 2:1 to DARO (n=955) or PBO (n=554) while continuing androgen-deprivation therapy. At the final data cutoff (Nov 15, 2019), OS and adverse events (AEs) were evaluated in pts with a median of ≤ and >6 comorbidities or ≤ and >10 concomitant medications in the double-blind period. HRs (95% CIs) were determined from univariate analysis using Cox regression. Results: The majority of pts had ≥6 comorbidities (53%; 795/1509) or received ≥10 concomitant medications (54%; 813/1509). For pts with ≤6 and >6 comorbidities, DARO prolonged OS vs PBO (HR 0.65 and 0.73, respectively). OS benefit of DARO vs PBO was consistent for pts with metabolic, cardiovascular (CV), and other comorbid disorders (HR range: 0.39–0.88). For pts receiving ≤10 and >10 concomitant medications, OS was prolonged with DARO vs PBO (HR 0.76 and 0.66, respectively). Subgroups of pts receiving concomitant medications for gastrointestinal/metabolic disorders, CV disease, urologic disorders, and pain/inflammation achieved similar OS benefit with DARO vs PBO (HR range: 0.45–0.80). Incidence of AEs and AEs leading to treatment discontinuation with DARO was comparable to PBO across subgroups by number of comorbidities and concomitant medications (Table). Conclusions: The OS benefit and safety of DARO remained consistent with that observed in the overall ARAMIS population, even in patients with a high number of comorbidities or concomitant medications. Clinical trial information: NCT02200614. [Table: see text]" @default.
• W4213213079 created "2022-02-24" @default.
• W4213213079 creator A5000159955 @default.
• W4213213079 creator A5002714845 @default.
• W4213213079 creator A5004503139 @default.
• W4213213079 creator A5007779528 @default.
• W4213213079 creator A5016270207 @default.
• W4213213079 creator A5017925159 @default.
• W4213213079 creator A5025116285 @default.
• W4213213079 creator A5041990261 @default.
• W4213213079 creator A5044273966 @default.
• W4213213079 creator A5048796030 @default.
• W4213213079 creator A5053829076 @default.
• W4213213079 creator A5055014935 @default.
• W4213213079 creator A5088518998 @default.
• W4213213079 date "2022-02-20" @default.
• W4213213079 modified "2023-09-26" @default.
• W4213213079 title "Efficacy and safety outcomes of darolutamide in patients with nonmetastatic castration-resistant prostate cancer with comorbidities and concomitant medications from ARAMIS." @default.
• W4213213079 doi "https://doi.org/10.1200/jco.2022.40.6_suppl.256" @default.
• W4213213079 hasPublicationYear "2022" @default.
• W4213213079 type Work @default.
• W4213213079 citedByCount "2" @default.
• W4213213079 countsByYear W42132130792023 @default.
• W4213213079 crossrefType "journal-article" @default.
• W4213213079 hasAuthorship W4213213079A5000159955 @default.
• W4213213079 hasAuthorship W4213213079A5002714845 @default.
• W4213213079 hasAuthorship W4213213079A5004503139 @default.
• W4213213079 hasAuthorship W4213213079A5007779528 @default.
• W4213213079 hasAuthorship W4213213079A5016270207 @default.
• W4213213079 hasAuthorship W4213213079A5017925159 @default.
• W4213213079 hasAuthorship W4213213079A5025116285 @default.
• W4213213079 hasAuthorship W4213213079A5041990261 @default.
• W4213213079 hasAuthorship W4213213079A5044273966 @default.
• W4213213079 hasAuthorship W4213213079A5048796030 @default.
• W4213213079 hasAuthorship W4213213079A5053829076 @default.
• W4213213079 hasAuthorship W4213213079A5055014935 @default.
• W4213213079 hasAuthorship W4213213079A5088518998 @default.
• W4213213079 hasConcept C121608353 @default.
• W4213213079 hasConcept C126322002 @default.
• W4213213079 hasConcept C197934379 @default.
• W4213213079 hasConcept C2778375690 @default.
• W4213213079 hasConcept C2779384505 @default.
• W4213213079 hasConcept C2780192828 @default.
• W4213213079 hasConcept C71924100 @default.
• W4213213079 hasConceptScore W4213213079C121608353 @default.
• W4213213079 hasConceptScore W4213213079C126322002 @default.
• W4213213079 hasConceptScore W4213213079C197934379 @default.
• W4213213079 hasConceptScore W4213213079C2778375690 @default.
• W4213213079 hasConceptScore W4213213079C2779384505 @default.
• W4213213079 hasConceptScore W4213213079C2780192828 @default.
• W4213213079 hasConceptScore W4213213079C71924100 @default.
• W4213213079 hasIssue "6_suppl" @default.
• W4213213079 hasLocation W42132130791 @default.
• W4213213079 hasOpenAccess W4213213079 @default.
• W4213213079 hasPrimaryLocation W42132130791 @default.
• W4213213079 hasRelatedWork W1995302457 @default.
• W4213213079 hasRelatedWork W2007674862 @default.
• W4213213079 hasRelatedWork W2056387366 @default.
• W4213213079 hasRelatedWork W2100060167 @default.
• W4213213079 hasRelatedWork W2128757265 @default.
• W4213213079 hasRelatedWork W2147892042 @default.
• W4213213079 hasRelatedWork W2901275087 @default.
• W4213213079 hasRelatedWork W4220780237 @default.
• W4213213079 hasRelatedWork W4248512896 @default.
• W4213213079 hasRelatedWork W43306833 @default.
• W4213213079 hasVolume "40" @default.
• W4213213079 isParatext "false" @default.
• W4213213079 isRetracted "false" @default.
• W4213213079 workType "article" @default.